This content is in French.
One vaccine, two viruses, a thousand hopes
10 juillet 2025
#COVID19 #SARSCoV2 #vaccineCOVID-19, caused by SARS-CoV-2, remains a major global health threat. While first-generation mRNA and adenoviral vector vaccines have significantly reduced mortality and the severity of acute forms, several limitations remain. Their effectiveness tends to decline against emerging variants, notably due to mutations in the spike protein, which is the primary target of indu
#COVID19 #SARSCoV2 #vaccine
COVID-19, caused by SARS-CoV-2, remains a major global health threat. While first-generation mRNA and adenoviral vector vaccines have significantly reduced mortality and the severity of acute forms, several limitations remain. Their effectiveness tends to decline against emerging variants, notably due to mutations in the spike protein, which is the primary target of induced immunity. Moreover, their adverse effect profile and associated logistical constraints—particularly the requirement for ultra-cold storage—limit their accessibility in many low-resource countries.
COVID-19, caused by SARS-CoV-2, remains a major global health threat. While first-generation mRNA and adenoviral vector vaccines have significantly reduced mortality and the severity of acute forms, several limitations remain. Their effectiveness tends to decline against emerging variants, notably due to mutations in the spike protein, which is the primary target of induced immunity. Moreover, their adverse effect profile and associated logistical constraints—particularly the requirement for ultra-cold storage—limit their accessibility in many low-resource countries.
Sign in to read the rest
Reserved for healthcare professionals, free registration.
Scientific reference
Abe, M., et al. (2025). A phase I […] study to evaluate immunogenicity and safety of a live attenuated tetravalent dengue vaccine (KD-382) in Flavivirus antibody-naïve healthy adults. Vaccine, 60, 127313
View the source
